Featured

According to the European Medicines Agency and other international health agencies, coronavirus vaccinations that have been modified to incorporate the omicron variant strain can provide better protection when administered as a booster. Following a meeting on June 30th, the...

The most prevalent kind of the disease, non-small cell lung cancer, has seen steady advancements in immunotherapies called checkpoint inhibitors during the past ten years. First, medications like Keytruda from Merck & Co., Opdivo from Bristol-Myers Squibb, and Tecentriq...

To address more recently circulating coronavirus strains, advisors to the U.S. Food and Drug Administration recently suggested altering the design of COVID-19 booster doses this fall. The next round of COVID booster shots should contain a component that combats the...

Combining the power of network with data paves the way for better logistical support for healthcare players.  The latest wave of COVID-19 infections has made its way across East Asia, with Hong Kong, Shanghai and Beijing, reporting record numbers...

A novel 3D printed methodology for extracting stem cells from bioreactors has been created by researchers at the University of Technology, Sydney, opening the door to the possibility of high-quality, mass-produced stem cells in Australia at a cheaper price. Due...

Novartis has committed to investing $250 million in research and development over the next five years in an effort to find a cure for malaria and other neglected tropical diseases (NTDs). CEO Vas Narasimhan remarked in a statement that...

In order to speed up research and development (R&D) for communicable diseases that disproportionately hurt lower-income nations, GSK plc announced a commitment of £1 billion over 10 years. This research will focus on novel and ground-breaking vaccines and medications to diagnose...